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Introduction
Despite therapeutic advances, atherosclerosis remains major cause of morbidity and mortality because of associated complications, such as coronary heart disease, ischemic stroke, or peripheral artery disease. Chronic inflammation induced by immune activation represents an important mechanism leading to atheromatous plaque formation. Different cellular populations may be involved in the pathogenesis of atherosclerosis, with monocytes/macrophages being thought to play the principal role. The first step in the process of athcrogcnesis, endothelial dysfunction, is followed by increased permeability of endothelial cells, loss of their anticoagulant activity and, last but not least, enhanced monocyte adhesion secondary to an increased endothelial expression of leukocyte adhesion molecules (1). The monocyte adhesion to the endothelium is followed by monocyte migration into the arterial wall and production of chemotactic, proinflammatory and cytotoxic mediators that further enhance atherogenesis. Advanced atheromatous plaque contains necrotic highly thrombogenic core with lipid-laden foam cells derived from macrophages. There is some evidence that unstable plaques have more extensive macrophage infiltration than stable plaques (2, 3). Increased circulating levels of acute phase proteins (C-reactive protein, serum amyloid A, interleukin-6, procalcitonin, or fibrinogen) as well as neopterin, an indicator of systemic immune activation, have been documented in patients suffering from atherosclerosis. The serum levels of these inflammatory markers may reflect the whole body burden of atherosclerotic tissue (4). The initial insult that induces the inflammatory response in atherosclerosis has not yet been identified, although some factors, such as oxidized low-density lipoprotein (LDL) cholesterol, hypcrhomocysteinemia, autoimmunity and infectious agents are suspected to play an important role. The effect of LDL-cholesterol on macrophages activity has been known for a long time.
Neopterin
(2-amino-4-hydroxy-6-[D-erythro-6-( l,2,3-trihydroxypropyl)J-pteridine) is a metabolite of guanosinc triphosphate, produced by macrophages upon stimulation with intcrferon-gamma (5). Measurement of neopterin concentrations may be used to assess macrophage activity. Neopterin production may reflect oxidative stress caused by immune system activation (6, 7). Measurement of neopterin is used for the monitoring of patients with disorders associated with immune activation, including cancer, acquired immune deficiency syndrome (AIDS), atherosclerosis, autoimmune diseases, or transplant rejections (6). There is a circadian rhythm of urinary neopterin with the peak in late night and early morning hours (8) .
Microalbuminuria denotes a limited urinary albumin excrction above physiological limits. Microalbuminuria is a marker of generalized vascular dysfunction (9) . Elevated urinary albumin level predicts not only renal disease, but it was shown to be related to clinical manifestation of atherosclerosis, e.g. ischemic heart disease (10), myocardial infarction (11) , left ventricular dysfunction (12. 13), silent myocardial ischemia (14) or ischemic stroke (15.16) . Microalbuminuria is a strong independent predictor of cardiovascular morbidity and mortality, and al I-cause mortality in patients with diabetes mellitus ( 1 7) as well as in non-diabetic patients (18, 19) . Microalbuminuria reflects the extent and severity of coronary artery disease (20) . The risk of cardiovascular event associated with conventional risk factors is more than doubled in the presence of microalbuminuria (10) . Conditions most frequently associated with microalbuminuria are identical with atherosclcrotic risk factors or develop as a consequence of the atherosclerotic process. Microalbuminuria is defined as urinary albumin/creatinine ratio of 2.5-30.0 mg/mmol in males and 3.5-30.0 mg/mmol in females. The prevalence of microalbuminuria in general European population is 5-7% (21, 22) . Recent data show that microalbuminuria is a strong independent predictor of coronary heart disease even when urinary albumin levels are within what is considered normal range of albumin excretion, and the level of 0.7 mg/mmol was recommended as the lower cutoff for urinary albumin/creatinine ratio in individual risk assessment of atherosclerotic cardiovascular disease (23) .
LDL-apheresis is a method of extracorporeal elimination of LDL-cholesterol. It is a life-saving treatment in patients with homozygous familial hypercholesterolemia and other severe primary lipoprotein disorders (hyperlipoprotcineimias) refractory to conventional treatment with lipid lowering drugs and lifestyle modification. If untreated, familial hypercholesterolemia homozygotes die around age of 20 years of complications of atherosclerosis, specifically myocardial infarction (24) . LDL-apheresis causes a massive reduction of LDL-cholesterol within several hours and, if performed regularly, can even achieve regression of atherosclerotic lesions (25) .
In the present study we tested the hypothesis that a rapid marked decrease of LDL-cholesterol level after a single LDL-apheresis procedure followed by a slow return to pretreatment levels during the time before the next procedure in patients with severe primary lipoprotein disorder is associated with the changes of systemic immune activity (assessed by measurement of urinary neopterin) and microvascular permeability for albumin.
Materials and methods

Patients and controls
Ten patients, 6 males and 4 females with severe primary lipoprotein disorder, treated by LDL-apheresis, were studied. The mean age (± standard deviation) was 44 Standard treatment with diet, life-style modification and lipid-lowering drags failed in all patients included in this study, and chronic intermittent extracorporeal LDL-cholesterol elimination was necessary to prevent accelerated progression of atheroslerosis. All patients have been treated with statins, in combination with fibrate in one patient and with bile-acid binding resin in two patients.
A group of 13 healthy subjects, 7 males and 6 females, aged 47 + 11 (range 25 -60 years) without any known serious pathology served as a control group.
LDL-apheresis
procedures LDL-apheresis was performed by immunoadsorption method in 8 patients and by rheopheresis in 2 patients. Patients' blood was taken from a peripheral venous access to the blood cell separator Cobe-Spectra (COBE BCT, Denver, CO, USA) that, acting as centrifuge, separates plasma and cellular components of the blood. In the immunoadsorption technique, plasma was pumped through affinity columns Lipopak (Pocard, Moscow, Russia), containing antibodies against the main lipoprotein of LDL-cholesterolapolipoprotein B| 00 . In rheopheresis, plasma is pumped through a filter that separates the lipoproteins and other large molecules. Filters Evaflux 4A a 5A (Kuraray Co., Osaka, Japan) were used. Technical details of the procedure have been described earlier by Klingel et a!. (26) . Purified plasma is mixed with blood cells separated earlier, and returned back to the patient via another peripheral vein. The adsorption is fully automated, the plasma flow through the adsorption columns is directed by a secondary device, ADA or Adasorb (Medicap, Ulrichstein, Germany). The duration of previous extracorporeal LDL-elimination therapy was 4.3 ± 2.8 years, range 0.2 -7.8, median 4.8 years. The interval to the next procedure was 23.4 ±7.8 days, median 26.0. This interval did not differ statisticaly from the interval between the previous and the current procedure (p = 0.938). Apheresis was started at 8 a.m., and the duration of the procedure was 3 -4 hours with 5000 -7100 ml of plasma (98 ± 18, range 78 -123 ml/kg, median 95 ml/kg) being washed. Anticoagulation was achieved with initial bolus of heparin and then by continuous acid citrate dextrose solution. The treatment was well tolerated.
Specimen collection First morning urine specimen for determination of neopterin and microalbuminuria was collected before the LDL-apheresis (DO), and subsequent first morning urine samples were collected on the L', 2 nd , 5 Ih , 14"' day after the procedure (D+l, D+2, D+5, D+14) with the last specimen collected before the next apheresis procedure (Dncxt). One specimen was also collected at 18:00 p.m. on the day of apheresis (DO 18:00). The samples were protected against light and immediately frozen and stored -20°C. Blood samples for evaluation of total, LDL-, HDLcholesterol and lipoprotein (a) were drawn from a peripheral vein before and immediately after the apheresis procedure and processed on the same day.
Urinary neopterin, creatinine and albumin analysis
After centrifugation (5 min, 1300 χ g) and diluting 100 μΐ of urine specimens with 1.0 ml of mobile phase containing 2 g of disodium-EDTA per liter, a 20 μΐ sample was injected on a column. Neopterin was measured in the urine specimens by reversed-phase high performance liquid chromatography system (Hewlett-Packard, Palo Alto, USA). Potassium phosphate buffer (15 mmol/1, pH 6.4) at flow rate of 0.8 ml/min was used as mobile phase. Neopterin was identified by its native fluorescence (353 nm excitation, 438 nm emission) by MPF-3 detector (Perkin-Elmer, Norwalk, USA) and quantified using an external standard. The concentration of neopterin in urine was expressed as neopterin/creatinine ratio (pmol/mol creatinine) (27) . Creatinine was determined in the same sample specimen by Jaffc kinetic réaction after dilution of sample 1:50 (v/v) on a Hitachi 716 analyser (Tokyo, Japan) with commercial kit (Boehringer, Mannheim, Germany) according the manufacturer's instructions. Urinary albumin was determined by Polyclonal Rabbit Anti-human Albumin kit (DakoCytomation, Glostrup, Denmark). The concentration of albumin in urine was expressed as albumin/creatinine ratio (mg/mmol).
Blood lipids analysis
Serum total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, lipoprotein (a) and triacylglycerols were determined with commercial kit (Roche) on Modular Roche analyser (Roche Diagnostics GmbH, Mannheim, Germany), according the manufacturer's instructions (27) . Non-HDL-cholesterol was calculated as the difference between the total cholesterol and the HDL-cholesterol.
Statistical analysis Table 2. Changes of serum lipids
As the data did not show normal distribution, nonparametric methods have been used. Wilcoxon rank sum test was used to assess longitudinal changes of the variables investigated. Spearman correlation coefficient (rj was used to assess relations between different evaluated parameters. Mann-Whitney rank sum test was used to test the difference between two cohorts of subjects. SigmaStat for Windows Version 3.0 (SPSS Inc., San Rafael, USA) was used to perform statistical analyses, and p-value < 0.05 was considered significant.
Results
Changes of lipids and their components during LDL-aphe res is
A highly significant (p = 0.001 ) decrease in serum lipids was observed after aphcrcsis. After LDL-apheresis, the mean (± standard deviation) decrease was 68.3 ± 9.3% for total cholesterol, 80.9 ± 12.2% for LDLcholesterol, 29.1 ± 10.9% for HDL-cholesterol, 77.9 ± 10.9 for non-HDL-cholesterol, 56.7 ± 20.6% for triglycerides, 78.1 ± 15.5% for apolipoprotein B, and 68.8 ± 33.7% for lipoprotein (a). The decrease of total cholesterol during the procedure correlated with the volume of processed plasma per kilogram of body weight (r s = 0.707, ρ = 0.0374). The concentrations before and after the apheresis and their changes during the procedure are summarized in the Non-HDL before -0.782 < 0.01 LDL-cholesterol = Low-density lipoprotein cholesterol. Non-HDL-cholesterol = non-high-density lipoprotein cholesterol. HDL-cholesterol = high-density lipoprotein cholesterol. Decrease (%) = decrease expressed in percent at 18 h on the day of apheresis (compared to pretreatmcnt levels). Decrease ( Abs) -absolute decrease at 18 h on the day of apheresis
Uri nan' neopt er in/creatinine ratio
The mean (± standard deviation) neoplerin creatinine ratio in controls was 123 ± 53. range 55 -228. median 108 μιηοΐ/mol creatinine. The mean (± standard deviation) urinary neopterin/creatinine ratio values of patients before and after apheresis are presented in the Figure 1 . Morning urinary neopterin/creatinine ratio before the treatment was significantly higher compared to neopterin/creatinine ratio of controls (p = 0.006). In contrast, the urinary neopterin/creatinine ratio in the evening after the apheresis did not differ from controls (p = 0.766). On subsequent days, this difference was also not statistically significant. Compared to the pre-apherctic levels, there was no significant difference in morning urinary neopterin/creatinine ratio in samples obtained during the period between two apheresis procedures (p > 0.05), with the The urinary neopterin/creatinine ratio decrease in the evening after the apheresis showed a significant negative correlation with pre-apheretic levels of total and LDL-cholesterol concentrations, with the decrease of total and LDL-cholesterol during the LDL-apheresis (Tabic 3) and with the volume of plasma per kilogram of body weight (r, = -0.778, ρ = 0.015). The decrease did not correlate with the pre-apheretic urinary neoptcrin/crcatininc ratio (r s = 0.261, ρ -0.446). Significant correlations were found for urinary neopterin/creatinine ratio and lipoprotein (a) on D+l (Table 3) . With the exception of D ι 1, no morning urinary neopterin/creatinine ratio correlated with any measured blood lipid fraction. No correlation of urinary neopterin/creatinine ratio with the age of patients and body mass index was observed. in two (20%) of patients, and the limit of 0.7mg/mmol. thought to be important in assessment of prognosis, was surpassed by another patient. In 7 other patients, the albumin/creatinine ratio did not reach this arbitrary limit. There was no significant difference between urinary albumin/creatinine ratio during the observation period, and no significant change occurred in the evening after apheresis (p > 0.3). Urinary albumin/creatinine ratio correlated strongly with evening urinary neopterin/creatinine ratio after the apheresis (Table 3) and with the total and LDL-cholesterol levels. Remarkable correlations between urinary albumin/-crcatininc ratio and serum lipid levels are summarized in the Table 4 . The correlation between urinary albumin/creatinine ratio and the magnitude of the urinary neopterin/creatinine ratio decrease in the evening DO was of bordeline significance (r s = -0.588, ρ = 0.067).
Urinary albumin/creatinine ratio
No correlation with any morning neopterin/creatinine ratio, triacylglyceides level and glycemia was observed.
Discussion
In the present study, moderately, but significantly elevated urinary neopterin levels were found in patients despite of intensive treatment with LDLapheresis and absence of clinical symptoms of progression of atherosclerosis. The elevation of urinary neopterin of these patients may be explained by atherosclerosis, as all the patients had evidence of atherosclerotic lesions and the presence of other disorders commonly accompanied by increased neopterin was excluded. This is in agreement with reports indicating that neopterin may be not only an indicator of the extent and stability (or activity) of atheromatous plaque, bui also a predictor of cardiovascular event risk. Increased neopterin concentrations have been reported in patients with atherosclerosis of the carotid (28) . coronary (29) or peripheral arteries (30) . Blood and urinary neopterin levels were increased in patients with acute coronary syndrome (31. 32). In other studies. neopterin concentrations correlated with the score of atigiographically determined atherosclerotic lesions, degree of myocardial ischemia (33) and with the number of complex coronary stenoses (34) . Baseline scrum neopterin concentrations were higher in women with ch rome stable angina, who subsequently developed cardiac events during follow up, than in those without cardiovascular events, similarly to patients with unstable angina (34) . Similar results were reported in patients with arterial hypertension without coronaiy artery disease who developed adverse events during follow-up (35), in patients who had non-Q-wave myocardial infarction (36) and in elderly population, where increased plasma neopterin levels predicted cardiovascular events (37) . Serum neopterin correlated with C-reacti\e protein in patients with coronary artery disease and was found to be a determinant of restenosis after revascularization (38) .
Impact of the LDL-apheresis on urinary neopterin concentrations in present study is questionable. Before starting the present study, we hypothesized that urinary neopterin will decrease after LDL-apheresis. This hypothesis was based on earlier studies demonstrating that LDL-cholesterol is a potent monocyte activator. LDL-cholcstcrol also possesses direct chemotactic activity for monocytes. Monocyte adhesion to (39) . Mononuclear cells exposed to oxidized LDL-cholcsterol species secrete factors that stimulate endothelial cells to express monocytes adhesion molecules and to produce monocyte chemotactie factors (40) . LDL-cholesterol decrease, caused by LDL-apheresis, is accompanied by a reduction of monocyte adhesion to endothelial cells (41 ) . Reduction of plasma concentrations of soluble leukocyte adhesion and chemotactic molecules was observed after a single procedure using different LDL-apheresis methods (42, 43, 44) . The decrease of soluble adhesion molecules was positively correlated with the total cholesterol decrease after the aphcresis, and rebound curves showed patterns similar to the total cholesterol rebound curves (43) . Statins, used as lipid lowering drugs, were found to supress interferon-gamma induced ncopterin formation in mononuclear cells in vitro (45) and, used in secondary prevention of coronary artery disease, to cause a decrease of adhesion molecules, ncopterin and C-reactive protein levels (46).
To our best knowledge, only one other study addressed the effect of extracorporeal elimination of cholesterol on neopterin concentrations. Vrecko et al. (47) studied serum and urinary neopterin in 30 patients treated by LDL-apheresis using the HELP method. A decrease in serum neopterin was observed, but urinary neopterin remained unchanged. Present data indicate that a single LDL-apheresis procedure, in addition to the rapid and large reduction of LDL-cholesterol, may also induce a decrease in urinary ncopterin, but, because of limited number of patients studied, do not allow a definitive conclusion in this respect. Patients with higher pre-apheretic cholesterol and more pronounced cholesterol decrease during the apheresis had larger volume of plasma processed. If the aphcresis is the cause of neopterin decrease, the decrease could be expected to be more pronounced in these patients compared to patients with small volume of plasma processed, but the findings are contrary to this hypothesis, with a negative correlation with plasma volume processed and the decrease of ncopterin. The significant decrease of urinary neopterin/ereatinine ratio in the evening after the apheresis compared to preapheretic levels eoincides with the diurnal rhythm of neopterin. The trend of decreased urinary ncopterin on D+l and D+2 did not reach statistical significance. A significant inverse correlation was found between the magnitude of the decrease of neopterin and total and LDL-cholesterol before the aphesis as well as decrease in total and LDL-cholesterol. Patients with milder hypercholesterolemia may have less extensive atherosclerosis. The systemic immune activation in these patients may be more affected by an acute decrease of serum cholesterol. In contrast, the atherosclerosis in patients with higher lipids may be more advanced and systemic immune activation resulting from atherosclerosis may be less influenced by acute fluctuations in lipid concentrations. The milder decrease of neopterin/creatinine ratio in the evening after apheresis in patients with more severe hypercholesterolemia can also reflect decreased circadian variation of neopterin urinary excretion due to enhanced basal monocyte activity, possibly from atherogenic plaques. In stable atherosclerosis, the quantity of neopterin produced could be a function of the total number of macrophages, which is proportional to the volume of stable plaques, and, consequently, basal neopterin production might be determined by basal macrophage activity (48) .
Urinary neopterin in the evening after apheresis correlated with microalbuminuria. It is possible that nadir of neopterin reflects residual systemic immune activation resulting from atherosclerosis that correlates with established indicators of vascular dysfunction like microalbuminuria. Microalbuminuria was constant during the short observation period, in contrast to results of Sinzinger and Kritz (49) who observed a reduction of albumin excretion after a single LDLapheresis procedure. In the present study, a nonsignificant rise was observed in the evening and on D+l. Patients with higher albumin excretion, regardless of the limit for microalbuminuria, had significantly higher cholesterol levels and higher evening neopterin. The results presented here differ from the report by Zouvanis et al. (50) , who found no microalbuminuria in 15 familial hypercholesterolemia patients and concluded that there is no association between microalbuminuria and coronary artery disease (CAD) in homozygous familial hypercholesterolemia. The authors hypothesized that microalbuminuria in combination with atherosclerosis and CAD is associated with insulin resistance. Insulin resistance is not present in familial hypercholesterolemia, contrary to patients with metabolic syndrome, characterized by elevation of serum triglycerides and decreased HDL-cholesterol. Hypercholesterolemia itself was thought not to lead to glomerular damage. Contrary to this hypothesis, we detected microalbuminuria in two familial hypercholesterolemia homozygotes and a third patient had reached the limit of 0,7 mg/mmol. There was no evidence of impaired glucose tolerance or elevated triacylglyceroles in these patients. In the only diabetic patient in our group, albumin was not even detectable in most of the samples. Microalbuminuria was found to be associated with high total and LDL-cholesterol by other authors (51 ) and in the present study it does not seem to be associated with metabolic syndrome.
In conclusion, the results indicate a possible connection between microvascular involvement evidenced by leak of albumin, macrophage activity reflected by increased urinary neopterin, and the severity of hypercholesterolemia. Because of the small number of patients studied, these results should be interpreted with caution and are of hypothesis-generating nature.
